Exactech increases guidance on increased sales; goes direct in France
This article was originally published in Clinica
Bone and joint restoration specialist Exactech has upped its first-quarter 2008 earnings guidance due to better-than-expected sales of its orthopaedic products. The Gainesville, Florida-based firm expects revenue for Q1 2008 to be around $40m, up 35% from the $29.6m recorded in the same quarter 2007. Consequently, Exactech said it anticipates Q1 earnings to be between $0.22-0.24 per share, ahead of its previous forecasts of $0.18-0.20. Exactech attributed the sales increase to strong uptake of its core products and the start-up of new distributors in Europe. The company recently closed its $11.1m acquisition of French orthopaedic products distributor France Medica, enabling it to go direct in France. The deal was announced in February (see Clinica No 1297, p 17).
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.